NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Medical Instruments & Supplies · USD

Becton, Dickinson and Company (BDX) Stock Analysis

Becton, Dickinson and Company (BDX) is a Medical Instruments & Supplies stock listed on NYSE and quoted in US Dollar.

BDX

$184.74

−$2.88 (−1.54%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BDX with… →

BDX Key Statistics

As of Sep 4, 2026
Trading
Open
$185.42
Previous Close
$187.62
Day's Range
184.05–187.13
52-Week Range
127.59–193.07
Volume
1.44M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.28
Valuation
Market Cap
$50.32B
P/E Ratio
31.96
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
13.90
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.11
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.24
EPS (ttm)Profit attributable to each share over the last twelve months.
5.78
Financials (FY)
Revenue (FY)
$21.84B+8.24%
Net Income (FY)
$1.68B−1.58%
Profit marginThe share of revenue left as profit after all costs and taxes.
4.19%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
272.39M
1-Year Return
+25.88%
Dividend and dates
Dividend
$4.20+2.27%
Ex-Dividend Date
September 9, 2026
Earnings Date
November 5, 2026estimated
Avg Volume
2.12M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BDX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+22.72%
2025−12.61%
2024−5.38%
2023−2.67%
2022+5.08%
2021+1.88%
2020−6.75%
2019+22.20%
2018+6.61%
2017+31.24%
2016 (partial year)−3.81%

As of September 4, 2026.

BDX Revenue and Earnings by Fiscal Year

FY ends September
Fiscal yearRevenueNet incomeNet margin
2025$21.84B$1.68B7.7%
2024$20.18B$1.71B8.4%
2023$19.37B$1.48B7.7%
2022$18.87B$1.78B9.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$21.84B$9.93B$2.99B$1.68B7.7%
2024$20.18B$9.13B$2.86B$1.71B8.4%
2023$19.37B$8.17B$2.42B$1.48B7.7%
2022$18.87B$8.48B$2.48B$1.78B9.4%

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

BDX Dividend History

$3.28+7.2% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$2.102—
2025$3.284+7.2%
2024$3.064+5.7%
2023$2.894+5.2%
YearDividends per sharePaymentsChange
2026 (partial year)$2.102—
2025$3.284+7.2%
2024$3.064+5.7%
2023$2.894+5.2%
2022$2.754+6.7%
2021$2.584+5.0%
2020$2.454+3.2%
2019$2.384+2.6%
2018$2.324+2.7%
2017$2.254+111.5%
2016$1.072—

Most recent payment: $1.05 per share, ex-dividend June 9, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

BDX Valuation vs Medical Instruments & Supplies Median

Median of 55 stocks
MetricBDXMedical Instruments & Supplies medianvs median
P/E31.9635.6110% below
P/S ratio2.243.1729% below
Profit margin4.19%0.85%3.3 pts above

Medians across 55 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Becton, Dickinson and Company (BDX) carries a market capitalisation of $50.32B. It is classified in the Medical Instruments & Supplies industry, within the Healthcare sector. The company reports 72,000 employees.

The most recent close on file for BDX is $184.74, dated September 4, 2026. That is −$2.88 (−1.54%) against the previous close. Over the past 52 weeks the price has ranged from $127.59 to $193.07. The latest close sits 44.8% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $21.84B. That is +8.24% against the prior fiscal year, when revenue was $20.18B. The same year closed with net income of $1.68B. That is −1.58% against the prior fiscal year. The reported profit margin is 4.19%. That is 3.3 percentage points above the Medical Instruments & Supplies median of 0.85%. Earnings per share on a trailing basis come to 5.78.

Across the 4 fiscal years on file, revenue moves from $18.87B in 2022 to $21.84B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

BDX trades at a trailing price-to-earnings ratio of 31.96. That is 10.26% below the Medical Instruments & Supplies median of 35.61. On forward earnings the ratio is 13.9. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.11. The price-to-sales ratio is 2.24. On price-to-sales that is 29.46% below the Medical Instruments & Supplies median of 3.17. 55 Medical Instruments & Supplies companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +25.88%. Measured over 10 years, that is +4.73% a year compounded. Beta against the wider market is reported at 0.28. Annualized volatility over the trailing 10 years is 23.9%.

Growth & Income

Shareholders receive a dividend, yielding 2.27% on the latest price. That is 1.3 percentage points above the Medical Instruments & Supplies median yield of 0.97%. The indicated annual rate is $4.20 a share. The ex-dividend date on file is September 9, 2026. Dividends are recorded for 11 calendar years; 2026 shows 2 payments totalling $2.10 a share. The year before, 2025, totalled $3.28 a share.

The strongest complete calendar year on file is 2017 at +31.24%; the weakest is 2025 at −12.61%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the price is +22.72%.

Peer Comparison

Becton, Dickinson and Company (BDX) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Becton, Dickinson and Company BDX $50.32B 32.0
Intuitive Surgical, Inc. ISRG $131.38B 42.4
Medline Inc. MDLN $49.23B 45.7
Alcon Inc. ALC $34.08B 55.1

The Medical Instruments & Supplies industry average P/E ratio is 35.6x. Becton, Dickinson and Company trades at a P/E of 32.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$131.38B

 MDLN

Medline Inc.

$49.23B

 ALC

Alcon Inc.

$34.08B

 RMD

ResMed Inc.

$32.94B

 WST

West Pharmaceutical Services, Inc.

$23.93B

 HOLX

Hologic, Inc.

$16.97B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Visit website →